Visium Asset Management’s Myriad Genetics MYGN Stock Holding History

Visium Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-31,060	Closed	-$1.06M	–	1176
2014 Q1	$1.06M	Buy	+31,060	New	+$962K	0.02%	467
2013 Q3	–	Sell	-153,103	Closed	-$4.11M	–	830
2013 Q2	$4.11M	Buy	+153,103	New	+$4.44M	0.1%	146

Other funds holding MYGN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Visium Asset Management's MYGN Position: Q2 2014 in Review

Visium Asset Management sold out of Myriad Genetics (MYGN) in Q2 2014, closing a stake of 31,060 shares — an estimated $1.06M sold.

Visium Asset Management first reported a position in MYGN in Q2 2013 and held it in 2 quarters. The position peaked at $4.11M in Q2 2013. 283 funds tracked by Wall St. Rank hold MYGN as of Q2 2014.

Visium Asset Management reported no remaining Myriad Genetics position as of Q2 2014 after selling out during the quarter.
Visium Asset Management sold 31,060 Myriad Genetics shares in Q2 2014, an estimated $1.06M.
Visium Asset Management first reported a position in Myriad Genetics in Q2 2013 and held it in 2 quarters.
Visium Asset Management's Myriad Genetics position peaked at $4.11M in Q2 2013.
283 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2014.

Based on Visium Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.